A New York based global life sciences investor
Advised a New York based global life sciences investor on a £20,000,000 investment into an Imperial College London spin-out company, VaxEquity Ltd, which accelerated the production of a vaccine to combat the Covid-19 pandemic and is dedicated to developing saRNA vaccines for serious and life-threatening diseases.
Data automation platform $2.8m in funding
Advising a data automation platform on $2.8m in seed funding to disrupt enterprise data strategy.
Commercialisation of intellectual property
Represented Medovate Limited, a vehicle established to enable the commercialisation of intellectual property generated from NHS Trusts in East Anglia.
Drug discovery companies
Company counsel for a number of drug discovery companies based in Cambridge who are backed by venture capital investors and advises them in respect of their funding rounds, day to day general corporate and restructuring requirements.
Involved in the commercialisation of technology from research institutions such as the University of Cambridge and Imperial Innovations representing founders and the spin out companies as well as investors in this process.
High growth technology companies
Company counsel for high growth technology companies advising them from formation to seed funding through to institutional investment.
Advises several accelerators providing programmes and early stage investment to start-up companies and have prepared their template documents for these investments and provides support to these programmes.
Series A fundings
Advises institutional investors in respect of seed and Series A+ fundings of high growth companies in multiple jurisdictions.
Provided several presentations about key issues facing early stage companies seeking venture capital investment.